Home | Back to newsletter main page

Bookmark and Share
Case Comprehensive Cancer Center Newsletter

February 25, 2013

gersonMESSAGE FROM THE DIRECTOR

Stan Gerson, MD
Director, Case CCC

Impact of Genomics on Cancer Diagnosis and Treatment: Open Drug Policy Forum

Last week, I wrote to Cancer Center members regarding the open drug policy forum that we are organizing on Monday, June 24, 2013 in the Wolstein Research Building Auditorium. For those of you who may have overlooked my email, I want to reiterate the importance of this exciting event. Next week, I will update you on confirmed attendees, and the progress of the agenda.

The day will feature panel discussions centered around the Impact of Genomics on Cancer Diagnosis and Treatment. We have assembled cancer experts from six Midwest cancer centers within 150 miles of Cleveland - Roswell Park Cancer Institute, University of Pittsburgh Cancer Institute, University of Michigan Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center, Karmanos Cancer Institute, and Case Comprehensive Cancer Center. We have also invited Sen. Sherrod Brown, Rep. Marcia Fudge, Sen. Rob Portman, the NCI, the FDA, and pharmaceutical and insurance company representatives (among others) to participate in this dynamic discussion.

A revolution in cancer care is emerging and will become mainstream over the next few years. We now have the ability to analyze the genetic changes in each person's tumor -- so-called precision or personalized cancer care. However, this often leads to a conundrum. The drug selected based on the genetic mutation may not have been approved for that type of tumor. While a physician can prescribe the drug, insurance and Medicare may not pay for it. Right now the complexity of these issues is disruptive to normal reimbursement policy.

In this forum we will discuss the following:

  1. How can we be sure that genetic tests are accurate enough to predict the utility of the drug?
  2. How can we possibly test every conceivable genetic test and drug combination, when each cancer is unique and one cancer may not predict the response of a different cancer?
  3. Is there any likelihood that this will be a more effective and less costly approach to treating patients, and will there be better outcomes?

Patients have begun to ask for genetic tests and now face the prospect of expecting access to drugs that cannot be reimbursed through insurance carriers. The ways that physicians at cancer centers are evaluating these issues will be described. We will ask the FDA to help us understand the review process for genetic tests, and will educate the public about the complexity of the process and the incredible potential for this new therapeutic approach. Legislation may be needed to change the way drugs are reimbursed based on individualized genetic testing. Now is the time to have the discussion about the approaches that could be taken.

I look forward to your participation in this forum. Registration will open earlier next month.


CASE CCC IN THE NEWS

Fatigue: The Forgotten Symptom?
Oncology Times - Feb 25, 2013
Mellar P. Davis, MD, of the Harry R. Horvitz Center for Palliative Medicine at the Taussig Cancer Institute at Cleveland Clinic Some agreed...

Robin Roberts' Return to Work Spotlights Resuming a Career After Cancer
CBS News - Feb 20, 2013
"We have to take a step back and really respect Robin Roberts for having the courage to talk about her treatments and going back to work," Dr. Mikkael Sekeres, director of the Leukemia Program at Cleveland Clinic's Taussig Institute in Ohio

Coleman, Ruhlman Gifts to University Hospitals Total $14.5 Million for Cancer and Women's Programs
Plain Dealer - Feb 18, 2013
"We're incredibly grateful to Kathy for her ongoing support and her real commitment to discovery and innovation," said Dr. Nathan Levitan, ...


ANNOUNCEMENTS

Dr. Dale Shepard Joins Alliance for Clinical Trials Committee

Dale ShepardDale Shepard, MD, PhD, co-director of the Taussig Oncology Program for Seniors (TOPS) and staff physician in the Department of Solid Tumor Oncology at the Cleveland Clinic, was selected as a member of the Cancer in the Elderly committee for the Alliance Cancer Control Program (CCP). This program, part of the Alliance for Clinical Trials in Oncology, conducts innovative scientific studies, including interventional, methodological, and health policy research, to help reduce the incidence, morbidity and mortality of cancer in broad populations. CCP is designed to help researchers better understand the factors that affect cancer risk, identify opportunities to prevent cancer or reduce the impact of cancer and/or its treatment on the patient, improve patient quality of life, and evaluate the feasibility and effectiveness of strategies to prevent and control cancer in academic settings, the community and in underserved populations.

Case CCC Protocol Templates Now Required

We have had a great success with our year-long run-in period of using Case CCC protocol templates for investigator-initiated studies. Effective immediately, Case CCC protocol templates are mandatory when developing investigator-initiated protocols, and must contain all protocol template elements and language. These requirements will be enforced by the Case CCC Protocol Review and Monitoring Committee at the time of protocol submission and review.

The Case CCC protocol templates (short and long versions) are available on the Case CCC website. They may also be accessed through links on the Clinical Research Portal or Clinical Trials Core Facility. If you have any questions about the templates, please contact Katarzyna Karelus at 216.844.4176 or kxk384@case.edu.


FUNDING OPPORTUNITIES/AWARDS

Doris Duke Innovations in Clinical Research Award

The Doris Duke Innovations in Clinical Research Award provides funding for early-stage research projects in clinical investigation to foster innovations in clinical research that advance the prevention, diagnosis and treatment of human disease. For 2013, the Doris Duke Charitable Foundation seeks proposals for cutting-edge clinical research that has the potential to catalyze innovative breakthroughs in sickle cell disease.

LOI Deadline: March 14
Proposal Deadline: May 13

Computational Genomic Epidemiology of Cancer Postdoctoral Training Program

The Case CCC invites applications to its 2-3 year NCI-funded Computational Genomic Epidemiology of Cancer Postdoctoral Training Program. The program combines a mentored cancer research project designed by the fellow in collaboration with their mentors with a specialized curriculum of formal didactic training and individualized longitudinal curriculum.

This program is designed to prepare trainees for careers as independent investigators engaged in research at the intersection of cancer research, genetics, epidemiology, biostatistics and computer science. Cancer researchers obtaining training will have the skills vital to decipher the complex pathways comprising genetic and environmental risk factors for disease, and will ultimately be able to provide clinicians and their patients with valuable information for the prevention and treatment of cancer.

Candidates with an MD, PhD, or MD/PhD degree, strong quantitative skills, and an interest in a career in genetics research are encouraged to apply.


MARK YOUR CALENDARS

Breast Cancer Program in Development Annual Retreat

Drs. William Schiemann and Lyndsay Harris, Co-Leaders of the Breast Cancer Program in Development, invite you to attend the program Annual Retreat on Monday, March 11 from 9 am-5:30 pm in the Dively Building on CWRU campus. The agenda is available on the Cancer Center website. Register today.

Melanoma Mini-Symposium

The Cleveland Melanoma Research Consortium, a new collaboration among basic researchers and clinicians at CWRU, UH, Cleveland Clinic, and VA Medical Center, is pleased to announce a mini-symposium devoted to melanoma research on Monday, March 11 from 3-7 pm in the Wolstein Research Building Auditorium.

This mini-symposium will provide a forum for physician scientists and biomedical researchers to foster communication and develop new collaborations on melanoma research. Research presentations will be organized around the following topics: Therapeutics/Drug Discovery, Cell Signaling and Environmental Effects, Immunology, and Epidemiology. Anyone in the Cancer Center community with an interest in melanoma research is encouraged to participate.

This event is sponsored by the Case Comprehensive Cancer Center, Skin Disease Research Center, and Department of Dermatology at Case Western Reserve University. A box meal will be provided. Please RSVP by Wednesday, March 6. The agenda is available on the Cancer Center website.

EVENTS

calendar

February 25

Pathology Research Seminar Series
Michael Weiss, MD, PhD, MBA
Professor and Chair, Biochemistry
Cowan-Blum Professor of Cancer Research
CWRU
Topic: How Insulin Binds: A First Glimpse of the Hormone-receptor Complex
12 pm WRB 1-413

Sequencing Data Interest Group (SDIG)
Matthew Cannon, PhD
Fellow, Serre Lab, Genetics
Cleveland Clinic
Topic: Genome-wide Expression and Epigenetic Analyses of Mice Born from Lean and Obese Mothers
2:30 pm WRB 1-403

Physiology and Biophysics Seminar
Mariela Mendez, PhD
Instructor, Div. of Hypertension and Vascular Research
Henry Ford Hospital
Topic: Molecular Regulation of Renin Release: Role of SNAREs
4 pm SOM / Robbins Building, E-501


February 26

Radiation Oncology Grand Rounds
Junran Zhang, MD, PhD
Assistant Professor, Radiation Oncology
CWRU/UH
Topic: DNA Double-strand Break Repair: From Genome Maintenance to Biomarker and Therapeutic Target
8:10 am Lerner B-181

Immunology Seminar Series: Faculty Candidate
Haitao Wen, PhD
Postdoctoral Research Associate, Microbiology and Immunology
University of North Carolina
Topic: NLRs in Metabolic Diseases and Cell Stress Response
12 pm WRB 1-413

Medicine Grand Rounds
John Gunstad, PhD
Associate Professor, Psychology
Kent State University
Topic: Neurocognitive Aspects of Cardiovascular Disease
12 pm Kulas Auditorium, Lakeside 5th Fl.


February 27

Hematology and Oncology Division Research Conference
Basem William, MD
Assistant Professor, Div. of Hem/Onc
CWRU/UH
Topic: Bone Marrow Neuropathy and Outcome of Autologous Stem Cell Transplantation: A Model to Study Hematopoietic Stem Cell Trafficking and Biology
8 am Lerner B-151

National Center for Regenerative Medicine Seminar
Sue Reynolds
eBioscience
Topic: Advanced Techniques for Intracellular Flow Cytometry
10 am WRB 3-136


February 28

Division of Hematology and Oncology Special Seminar
David E. Avigan, MD
Associate Professor, Div. of Hem/Onc
Harvard University/Beth Israel Deaconess Medical Center
Topic: Challenges in Vaccine Therapy
9 am Lerner B-151


March 1

Hematology/Oncology Fellows Conference/Curriculum Series
Topic: TBD
8 am Wearn 137/Breen Conference Rm.

Taussig Cancer Institute Grand Rounds
Marcos de Lima, MD
Professor, Div. of Hem/Onc
CWRU/UH
Topic: Cord Blood Transplantation
8 am R3/002-003 Cleveland Clinic

Cancer Center Seminar Series
Andrew Sloan, MD
Director, Brain Tumor & Neuro-Oncology Center, Neurological Institute
Associate Professor and Vice Chairman, Neurological Surgery
CWRU/UH
Topic: Glioma Stem Cells: Biology Clinical Implications & Results of Early Stage Clinical Trials
12 pm BRB 105

Cancer Center Research in Progress
Cheng-Kui Qu, MD, PhD
Associate Professor, Div. of Hem/Onc
CWRU/UH
Topic: Targeting Protein Tyrosine Phosphatase SHP2 (PTPN11) for the Treatment of Childhood Leukemia
4 pm WRB 3-136

 

 

Case CCC Calendar

LRI Calendar


UPCOMING CANCER CENTER SYMPOSIUMS & EVENTS

Breast Cancer Program in Development Annual Retreat
March 11
9 am-3 pm Dively Building

Melanoma Mini-Symposium
March 11
3-7 pm Wolstein Research Building
Agenda
Registration

IMPACT: Improving Sickle Cell Patient Adherence Through Collaborative Teaching
March 23
Wolstein Research Building
Brochure and Registration

Breast Cancer Conference
May 17
Hilton Cleveland East

Impact of Genomics on Cancer Diagnosis and Treatment: Open Drug Policy Forum
June 24
9 am - 3 pm Wolstein Research Building

Annual Cancer Center Scientific Retreat
July 11-12
Location TBD

 

ADDITIONAL UPCOMING SEMINARS & EVENTS

National GvHD Health Symposium
November 1


PREVIOUSLY ANNOUNCED OPPORTUNITIES

QuadW Foundation-AACR Fellowship for Clinical/Translational Sarcoma Research
Deadline Extended: February 26

AACR Clinical and Translational Cancer Research Fellowships
Deadline: February 27

Leukemia and Lymphoma Society Translational Research Program
LOI Deadline: March 1
Full Application Deadline: March 15

Alex's Lemonade Stand Foundation Pediatric Oncology Student Training Program
Deadline: March 4

Childhood Brain Tumor Foundation
Deadline: March 12

American Society of Hematology Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation
Deadline: March 14

Case CCC ACS IRG
(LOI Deadline: February 18)
Application Deadline: April 5

Translational Technology Concept Studies of Circulating Tumor and Endothelial Cells (CTC/CEC)
Deadline: Open

AACR Scholar-in-Training Awards - Other Conferences and Meetings
Deadline: Open

Case CCC Protocol Specific Research Support (PSRS)
Deadline: Open

International Union Against Cancer (UICC) International Cancer Technology Transfer Fellowships
Application Deadline: Open

International Waldenstrom's Macroglobulinemia Foundation (IWMF) Research Grant Program
Application Deadline: Open

James S. McDonnell Foundation Collaborative Activity Awards
Deadline: Open

NCI Short-Term Scientist Exchange Program
Application Deadline: Open

SAIC-Frederick Support of the Cancer Genome Atlas Program
Application Deadline: Open

Solving Kids' Cancer Therapeutic Development Initiative
Application Deadline: Open


NIH BULLETIN – Notices and Funding Opportunities

Request for Information (RFI): Inviting Comments and Suggestions on the Implementation of the Recommendations of the Advisory Committee to the NIH Director Working Group on the Biomedical Research Workforce (NOT-OD-13-045)

National Cancer Institute (NCI) is participating in PA-13-118 Mechanisms, Models, Measurement, & Management in Pain Research (R01)(NOT-CA-13-003)

National Cancer Institute (NCI) is participating in PA-13-119 Mechanisms, Models, Measurement, & Management in Pain Research (R21)(NOT-CA-13-004)

National Cancer Institute (NCI) is participating in PA-13-117 Mechanisms, Models, Measurement, & Management in Pain Research (R03)(NOT-CA-13-005)

Collaborative Human Tissue Network (CHTN) (UM1)(RFA-CA-13-007)

Request for Information (RFI): Training Needs in Response to Big Data to Knowledge (BD2K) Initiative (NOT-HG-13-003)

Request for Information (RFI): FDA Collaborating Centers of Excellence in Regulatory Science and Innovation (FDA-CERSI)(NOT-FD-13-008)

PHS 2013-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])(PA-13-089)

PHS 2013-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])(PA-13-088)

PHS 2013-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])(PA-13-088)

PHS 2013-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])(PA-13-089)

Produced by:
Gillian Irwin Todd
11100 Euclid Avenue, Wearn 149
Cleveland, Ohio 44106-5065
216.844.8317 phone
216.844.7832 fax
gillian.irwin@case.edu

HELP US HELP YOU!

If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades!

Send items to gillian.irwin@case.edu.